Effects of Short- and Long-Term Soy Protein Feeding on Hepatic Cytochrome P450 Expression in Obese Nonalcoholic Fatty Liver Disease Rat Model

Melisa Kozaczek 1,2,3, Walter Bottje 2, Diyana Albataineh 2 and Reza Hakkak 1,3,4*

1 Department of Dietetics and Nutrition, University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2 Department of Poultry Science and The Center of Excellence for Poultry Science, University of Arkansas, Fayetteville, AR, United States, 3 Arkansas Children's Research Institute, Little Rock, AR, United States, 4 Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR, United States

Obesity can lead to chronic health complications such as nonalcoholic fatty liver disease (NAFLD). NAFLD is characterized by lipid aggregation in the hepatocytes and inflammation of the liver tissue as a consequence that can contribute to the development of cirrhosis and hepatocellular carcinoma (HCC). Previously, we reported that feeding obese Zucker rats with soy protein isolate (SPI) can reduce liver steatosis when compared with a casein (CAS) diet as a control. However, the effects of SPI on cytochrome P450 (CYP) in an obese rat model are less known. In addition, there is a lack of information concerning the consumption of soy protein in adolescents and its effect in reducing the early onset of NAFLD in this group. Our main goal was to understand if the SPI diet had any impact on the hepatic CYP gene expression when compared with the CAS diet. For this purpose, we used the transcriptomic data obtained in a previous study in which liver samples were collected from obese rats after short-term (eight-week) and long-term (16-week) feeding of SPI (n = 8 per group). To analyze this RNAseq data, we used Ingenuity Pathway Analysis (IPA) software. Comparing short- vs long-term feeding revealed an increase in the number of downregulated CYP genes from three at 8 weeks of SPI diet to five at 16 weeks of the same diet (P ≤ 0.05). On the other hand, upregulated CYP gene numbers showed a small increase in the long-term SPI diet compared to the short-term SPI diet, from 14 genes at 8 weeks to 17 genes at 16 weeks (P ≤ 0.05). The observed changes may have an important role in the attenuation of liver steatosis.

Keywords: soy protein isolate, liver steatosis, obesity, cytochrome P450, NAFLD

INTRODUCTION

Obesity is a multifactorial disease that can result from an imbalance between high energy intake and low energy expenditure due to reduced physical activity (1). Obesity can increase the clinical risks for developing other health conditions, such as cardiovascular disease, insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) (2, 3). NAFLD is one of the most frequent and widespread causes of liver disease in the United States and is commonly complementary in
patients with other metabolic disorders (4–6). The prevalence of NAFLD ranges from 10 to 30% worldwide and affects 30% of the population in the United States, thus becoming an international health epidemic (4, 7). The pathology of NAFLD represents a spectrum of stages from mild steatosis to nonalcoholic steatohepatitis (NASH), often accompanied by inflammation, and fibrosis or cirrhosis that can lead to hepatocellular carcinoma (HCC) if left untreated (4, 8, 9). NAFLD is a multisystem disease that develops from insulin resistance, caused by an excessive accumulation of lipids in hepatocytes, followed by the alteration of oxidative stress, the accumulation of endotoxins, and the accumulation of inflammatory cytokines in the liver (10, 11).

The liver is the primary organ in the human body that functions to metabolize and detoxify xenobiotic molecules, including exogenous toxins and drugs (12). The cytochrome P450 (CYP) superfamily is one of the main drug-metabolizing families of heme-containing enzymes, playing a key role in protecting the organism from toxic compounds, both endogenous and exogenous (13, 14). The CYP superfamily receives its name from the fact that they exhibit a maximum absorbance at the wavelength of 450 nm when bound to carbon monoxide (15). This conspicuous set of proteins found in all biological kingdoms comprises oxidases, reductases, and hydrolases: most of them are part of Phase I drug and toxin metabolism that serves in making the target compounds more hydrophilic and more easily excreted either in the bile or in the urine (12, 15). In NAFLD, there are altered functions and storage of adipose tissues, upregulation of proinflammatory biomarkers, production of reactive oxygen species (ROS), and changes in gene expression (16). Major families of CYP proteins are known to be differentially expressed in the liver throughout the progression of NAFLD (17, 18). In addition, the dietary composition can alter the expression and activity of many CYP proteins, which can, in turn, influence the drug metabolism and disease prevalence (19, 20). In this regard, soy proteins have been extensively studied, mostly due to their correlation with health benefits such as the prevention of chronic diseases and some types of cancer (21, 22).

Soybeans are the main source of protein in Asian diets, vegetarians, and soy infant formula (23). Multiple studies concerning the effects of soy diet in rat models have been performed; however, to our knowledge, most of this research has been carried out on nonobese rat lines (24–26), and very little is known concerning the effects of soy protein isolate (SPI) diet in an obese rat model and its preventive effects against NAFLD (27). There is also a need for more information pertaining to the inclusion of soy proteins in the diets of infants and adolescents (28). Thus, this study focuses on the impact an SPI diet has in obese juveniles (15 weeks old, 8 weeks on diet, short-term SPI diet) and adult rats (23 weeks old, 16 weeks on diet, long-term SPI diet). We can extrapolate both the short- and long-term results to adolescents and adults, respectively. Recently, we reported that SPI had a protective effect against liver steatosis (29) and proposed that SPI reduces inflammation and enhances the lipid transport out of the liver in obese Zucker rats (30, 31).

There are very limited data on the effects of soy protein feeding in the NAFLD model on the expression of CYP450; therefore, the main objectives of this study were to investigate the effects of short- and long-term SPI on hepatic CYP450 expression.

MATERIALS AND METHODS

Ethics Statement

This study used the methods described in the studies by Hakkak et al. (29) and Kozaczek et al. (32), and the description of the methods partly reproduces their wording (29, 32). The protocol for this study (code number 3242) was approved by the Institutional Animal Care and Use Committee at the University of Arkansas for Medical Sciences (IACUC) on December 6, 2011.

Experimental Design

Six-week-old male Zucker rats (n = 8–9 per group) were purchased from Envigo (Indianapolis, IN). After 1 week of acclimation, 7-week-old rats were randomly assigned to diets containing either SPI casein (CAS, control) as the main protein source for 8 and 16 weeks. Rats were weighed two times per week and had ad libitum access to feeding and water. After 8 weeks of diet, when the rats were 15 weeks old, half of the rats in the SPI group and the CAS group were sacrificed. In this stage, rats were juveniles and the results can be extrapolated to adolescents. The remaining obese Zucker rats continue to be on their respective diets (either SPI or CAS) for another 8 weeks to double the amount of time on experimental feeding, making a total of 16 weeks of diet. After 16 weeks on experimental diets, when the rats were 23 weeks old, all the rats were sacrificed. Rats were anesthetized with carbon dioxide and euthanized by decapitation at the end of each experiment, at 8 (15-week-old rats) and 16 weeks (23-week-old rats) of SPI diet. Blood and liver samples were collected. Liver tissues were immediately flash-frozen with liquid nitrogen and stored at −80°C. Envigo prepared both diets, and the composition of both diets is described in Table 1.

Transcriptomics/CYP Analysis

The methods for RNA extraction from the liver samples and the pipeline followed to generate the RNAseq data are described in Kozaczek et al. (32). More than 1,200 transcripts were differentially expressed (>1.3-fold difference and P < 0.05) and later evaluated with Ingenuity Pathway Analysis program (IPA, Qiagen, CA) to help in the analysis and understanding of the global gene expression data. To illustrate the differentially expressed genes in relative values, we used the scientific graphing software Graph Pad Prism 8.4.3 (La Jolla, CA) and Student’s t-test. Differences were considered significant at P < 0.05. Transcriptomic data are available in the Gene Expression Omnibus database (GEO accession number GSE158553). The transcriptomic analysis is based on the statistical analysis obtained using the IPA application to compare the gene expression of CYP450 in results of the SPI diet with that in the results of the CAS control diet. IPA software analysis algorithm generates the predictions of activation or inhibition of upstream regulator molecules and downstream functions calculating two statistical measures. These two statistical measures are based on both the scientific literature stored in the Qiagen knowledge database and the activation state of the molecules in our datasets.
The average initial body weight (BW) at the beginning of the experiment (7-week-old rats) for the CAS group expressed in grams (g) was 199 ± 17, whereas it was 202 ± 17 for the SPI group. At 8 weeks of diet, the final BW for the CAS group was 548 ± 66, whereas the BW for CAS at 16 weeks of diet was 658 ± 62. The final BW for the SPI group after 8 weeks of diet was 605 ± 55, whereas the final BW for the SPI group at 16 weeks of diet was 735 ± 25. The average liver weight for the CAS group at 8 weeks of diet was 25.7 ± 1.5 and that for the CAS group at 16 weeks of diet was 30.9 ± 4.9.

Liver weight for the SPI group at 8 weeks of diet was 20.9 ± 3.9, and the liver weight for the SPI group at 16 weeks of diet was 22.0 ± 2.1. SPI-fed rats had substantially lower liver weight than CAS-fed rats after both 8 and 16 weeks of SPI feeding (29). Steatosis was calculated as a score of 1 to 4 based on the observed lipid accumulation within hepatocytes: 1) <25%, 2) 25–50%, 3) 50–75%, and 4) >75%. After 8 weeks of experiment (15-week-old rats, the short-term SPI feeding), the SPI-fed rats had a liver steatosis score of 2.10 ± 1.0, whereas the CAS-fed rats had a steatosis score of 3.20 ± 0.5 (P < 0.05). After 16 weeks of experiment (23-week-old rats, the long-term SPI feeding), SPI-fed rats had a steatosis score of 1.70 ± 0.7, which was significantly lower (P < 0.001) than the CAS-fed rats with a steatosis score of 3.4 ± 0.9. Serum inflammatory biomarkers ALT and AST levels were published in the study by Hakkak et al. (29).

Previously, we reported the results of feeding SPI-based diets in both male (29) and female (35, 36) Zucker rats, where the SPI-fed rats (females and males) were equally protected against liver steatosis compared to the CAS-fed rats. In addition, we reported the effects of SPI feeding for eight and 16 weeks on targeted liver gene expression obtained by RNAseq and validation using the real-time PCR (RT-PCR) in obese Zucker rats (32, 37). In this report, we show that feeding SPI for short term and long term affected the expression of CYP genes in the livers of Zucker rats compared to those fed with CAS.

We compared which CYP genes were upregulated and downregulated at 8 and 16 weeks of SPI diet compared to the CAS diet (Figure 1). The statistics measurements used in this study were the comparison of p-values, relative fold changes, and Z-scores generated through analysis with IPA software. All the results presented in this study were compared and are relative to the expression levels in the CAS control diet results. Most of the CYP genes belong to one of the following main families of CYP, CYP1, CYP2, and CYP3, with some exceptions belonging to CYP4 and CYP5 for the downregulated CYP genes (Table 2), and CYP7 subfamily in the upregulated group (Table 3). After 8 weeks of SPI feeding, only three CYP genes were downregulated: Two genes belong to the CYP2C subfamily and the other gene belongs to the CYP3A subfamily. By the 16th week, five CYP genes were downregulated in the SPI-fed group (Table 2). On the other hand, the number of upregulated CYP genes did not change significantly between 8 and 16 weeks of the SPI diet. Rats fed with SPI diet for 8 weeks presented 14 upregulated CYP genes (Table 3), whereas the rats fed with SPI for 16 weeks presented 17 upregulated CYP genes.

In addition, we report a predicted activation of aryl hydrocarbon receptor (AHR) linked to the subsequent activation or upregulation of various CYP genes (Figures 2, 3). This prediction of AHR activation was obtained with the “regulator
CYP2C18 activating or inhibiting effect over the function at the bottom (inflammation-causing steatosis that can later develop into fibrosis and NASH and finally lead to cirrhosis and HCC). The master regulator would ultimately have an effect on a phenotype or function at the bottom (Figure 3A, activation or inhibition (AHR in this case), dataset molecules in the middle, interactions of genes in the scientific literature stored in the IPA database, generates directional networks based on our input data and a wide range of scientific literature stored on the IPA database, thus generating a hypothesis on how specific phenotypes or functions could be regulated in our dataset by activated or inhibited upstream regulators (genes). The generated networks are displayed in a hierarchical manner, with a master regulator at the top (AHR in this case), dataset molecules in the middle, and a phenotype or function at the bottom (in Figure 3, the functions are the conversion of lipid and the recruitment of phagocytes). The master regulator would ultimately have an activating or inhibiting effect over the function at the bottom through the downstream molecules that are present in the dataset. Figure 2 shows a prediction legend for the interpretation of regulator networks. Red molecules are upregulated, whereas green molecules are downregulated. Orange molecules are predicted to be activated and blue molecules are predicted to be inhibited as a result of the interaction with the master regulator. Uninterrupted arrows indicate the direct molecule–molecule interactions, while dashed arrows indicate that between those two molecules are intermediary molecules or steps. Gray arrows are displayed when there are not enough reports on the interactions of genes in the scientific literature stored in the IPA knowledge database; therefore, IPA software does not predict activation or inhibition (Figure 3A). Figure 3 shows how AHR activation was predicted to indirectly activate or inhibit two main metabolic functions under SPI feeding: conversion of lipid (lipid metabolism)—predicted to be activated (Figure 3A), and recruitment of phagocytes (inflammatory response)—predicted to be inhibited (Figure 3B).

**DISCUSSION**

The first signs of NAFLD are a detrimental aggregation of lipids within the liver cells, leading to insulin resistance and inflammation-causing steatosis that can later develop into fibrosis and NASH and finally lead to cirrhosis and HCC (38, 39). Studies have shown a dysregulation in CYP proteins during the progression of NAFLD (40). CYP protein families are found in high concentrations in the liver and are notably responsible for drug and exogenous substrate metabolism, and important functions in our dataset. The regulator effect algorithm connects upstream regulators with downstream molecules and downstream functional outcomes. It can provide an understanding of how the activation or inhibition of an upstream regulator could be affecting the expression of other molecules and important functions in our dataset. The regulator effect algorithm generates directional networks based on our input data and a wide range of scientific literature stored on the IPA database, thus generating a hypothesis on how specific phenotypes or functions could be regulated in our dataset by activated or inhibited upstream regulators (genes). The generated networks are displayed in a hierarchical manner, with a master regulator at the top (AHR in this case), dataset molecules in the middle, and a phenotype or function at the bottom (in Figure 3, the functions are the conversion of lipid and the recruitment of phagocytes). The master regulator would ultimately have an activating or inhibiting effect over the function at the bottom through the downstream molecules that are present in the dataset. Figure 2 shows a prediction legend for the interpretation of regulator networks. Red molecules are upregulated, whereas green molecules are downregulated. Orange molecules are predicted to be activated and blue molecules are predicted to be inhibited as a result of the interaction with the master regulator. Uninterrupted arrows indicate the direct molecule–molecule interactions, while dashed arrows indicate that between those two molecules are intermediary molecules or steps. Gray arrows are displayed when there are not enough reports on the interactions of genes in the scientific literature stored in the IPA knowledge database; therefore, IPA software does not predict activation or inhibition (Figure 3A). Figure 3 shows how AHR activation was predicted to indirectly activate or inhibit two main metabolic functions under SPI feeding: conversion of lipid (lipid metabolism)—predicted to be activated (Figure 3A), and recruitment of phagocytes (inflammatory response)—predicted to be inhibited (Figure 3B).

**DISCUSSION**

The first signs of NAFLD are a detrimental aggregation of lipids within the liver cells, leading to insulin resistance and inflammation-causing steatosis that can later develop into fibrosis and NASH and finally lead to cirrhosis and HCC (38, 39). Studies have shown a dysregulation in CYP proteins during the progression of NAFLD (40). CYP protein families are found in high concentrations in the liver and are notably responsible for drug and exogenous substrate metabolism,

### TABLE 2 | Downregulated CYP expression comparison between soy protein isolate (SPI) vs. casein (CAS) feeding at 8 and 16 weeks of diet.

| Gene      | 8 weeks p-value | 16 weeks p-value |
|-----------|----------------|-----------------|
| CYP2C12   | 1.76 × 10⁻¹⁷   |                |
| CYP2C18   | 1.12 × 10⁻¹⁰   |                |
| CYP3A62   | 1.75 × 10⁻⁰⁴   |                |

All p-values were statistically significant (p ≤ 0.05).

### TABLE 3 | Upregulated CYP expression comparison between SPI versus CAS feeding at 8 and 16 weeks of diet.

| Gene      | 8 weeks p-value | 16 weeks p-value |
|-----------|----------------|-----------------|
| CYP3A7    | 5.48 × 10⁻⁰⁷   |                |
| CYP2C13   | 4.58 × 10⁻⁰⁵   |                |
| CYP1A2    | 5.40 × 10⁻⁰⁵   |                |
| CYP2D26   | 5.17 × 10⁻⁰⁴   |                |
| CYP2D6    | 1.31 × 10⁻⁰³   |                |
| CYP2D22   | 1.91 × 10⁻⁰³   |                |
| CYP2B6    | 2.05 × 10⁻⁰³   |                |
| CYP2B9    | 3.12 × 10⁻⁰³   |                |
| CYP2D1    | 9.52 × 10⁻⁰³   |                |
| CYP2C19   | 1.17 × 10⁻⁰²   |                |
| CYP2C23   | 1.25 × 10⁻⁰²   |                |
| CYP4F8    | 5.00 × 10⁻⁰⁰   |                |
| CYP2C8    | 5.39 × 10⁻⁰²   |                |
| CYP7A1    | 5.98 × 10⁻⁰²   |                |
| CYP1A2    | 5.97 × 10⁻¹²   |                |
| CYP2B9    | 3.92 × 10⁻⁰⁵   |                |
| CYP7B1    | 1.07 × 10⁻⁰⁶   |                |
| CYP3A7    | 1.68 × 10⁻⁰⁶   |                |
| CYP2A8    | 4.02 × 10⁻⁰⁶   |                |
| CYP4F8    | 8.98 × 10⁻⁰⁵   |                |
| CYP2C8    | 1.52 × 10⁻⁰²   |                |
| CYP2C9    | 1.65 × 10⁻⁰²   |                |
| CYP2B6    | 1.80 × 10⁻⁰²   |                |
| CYP2A12   | 2.04 × 10⁻⁰²   |                |
| CYP2D6    | 3.85 × 10⁻⁰²   |                |

Values in italic font were statistically significant. Values not italicized were borderline significant (p ≤ 0.05).
detoxification of environmental chemicals, bioactivation of carcinogens, and the biosynthesis of endogenous substrates (41, 42). In addition, they play significant roles in metabolizing noncellular materials, cholesterol, vitamin D, arachidonic and retinoic acids, eicosanoids, and the biosynthesis of bile acids and steroids (43). CYP proteins function to metabolize fatty acids by hydroxylating terminal carbons in the fatty acid chain (44).

During the process of metabolizing fatty acids, the hydroxylated fatty acids are converted into dicarboxylic acids that are then metabolized by the beta-oxidation system in the peroxisomes of liver cells (45). This system converts the dicarboxylic acid to the shorter fatty acids that are transported to the mitochondria for the final oxidation step. The energy supplied by this oxidation is used for the lipid synthesis or are transported to the peripheral tissues when the energy production is low (46). In the liver, the hydroxylation of fatty acids and their metabolism are used as a mechanism for energy production, lipogenesis, and structural lipid synthesis (46). In the normal human liver, the factors that influence the expression and regulation of CYP proteins are imbalances of endocrine hormones, poor diet, genetic polymorphism, and environmental factors (47). Chronic liver disease is a dominant force that impairs CYP drug metabolism function in the liver cell (47). Altered CYP protein regulation and expression are positively correlated with the severity of liver disease, most notably in NAFLD (47). Decreased CYP protein activity directly affects the metabolism of the therapeutic drugs that can have a negative impact on cell toxicity (47). In contrast, increased activity of CYP enzymes can lead to an excessive metabolism of cellular substrates that can cause an increase of ROS in the cell (47). Multiple individual CYP proteins have been associated with particular disorders (48). For example, overexpression of CYP7A1 seems to protect against atherosclerosis by reducing the accumulation of visceral fat among other factors (48), whereas downregulation of CYP1A2 has been correlated with the progression of HCC (49). CYP1A2 and CYP7A1 were highly upregulated in this study at both eight and 16 weeks of SPI feeding (Figure 1 and Table 3), showing an increase in their expression in the long-term feeding.

**FIGURE 2** | IPA Prediction legend to help in the understanding of regulator networks.

**FIGURE 3** | Regulator networks illustrating the role of aryl hydrocarbon receptor (AHR) as the master regulator in a component of lipid metabolism and inflammatory response. (A) Conversion of lipid (Z-score = 2.09, \( p = 2.77 \times 10^{-08} \)), predicted to be activated in SPI diet; (B) recruitment of phagocytes (Z-score = −2.31, \( p = 2.10 \times 10^{-05} \)), predicted to be inhibited. Both networks have in common the upregulation of CYP1A2 as indirect result of AHR activation (activation Z-score = 2.15, \( p = 4.20 \times 10^{-11} \)). Genes in pink or red were upregulated in the SPI-fed rats, whereas those in green were downregulated in SPI- vs. CAS-fed rats. Gene names and fold differential expression in the regulatory networks are CYP1A2 (Cytochrome P450 Family 1 Subfamily A Member 2, 1.91), CYP2B6 (Cytochrome P450 Family 2 Subfamily B Member 6 1.51), Mt1 (Metallothionein 1, 1.52), CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8, 1.41), TGFB1 (transforming growth factor beta 1, 1.33), MMP2 (matrix metallopeptidase 2, 1.96), PDE4B (phosphodiesterase 4B, −1.93), and THBS1 (thrombospondin 1, −1.63).
CYP1, CYP2, and CYP3 protein family members dominantly metabolize an estimated 75% of all hepatic drugs in humans and animals (50, 51). In addition, animal studies suggest that an accumulation of lipids in hepatocytes can impair CYP protein function (52) as found in patients with NAFLD that present with a downregulation of nuclear receptors during the transcriptional regulation of Phase I and Phase II drug-metabolizing enzymes (53). In addition, it has been established in recent years that CYP epoxygenases, the enzymes catalyzing the oxidation of polyunsaturated fatty acids (PUFA) to PUFA epoxides, play an essential role in the regulation of inflammation through the production of these reactions, which can act as lipid mediators (54). Various CYP subfamilies have been categorized as CYP epoxygenases, including CYP1A1, CYP2B, CYP2C, CYP2E, and CYP2J2 subfamilies. In humans, CYP2C8, CYP2C9, CYP2C19, and CYP2J2 isoforms have been recognized as CYP epoxygenases converting arachidonic acid into different types of PUFA epoxides (55). In this study, CYP2C8, CYP2C9, and CYP2J2 (Table 3) were upregulated at both 8 and 16 weeks in SPI-fed obese rats. Validation by RT-PCR of CYP2C12 expression (16 weeks, p = 6.06 × 10^-08) was previously reported in the study of Kozaczek et al. (32). CYP7A1, CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP4F8 mRNA enzymatic activity and protein expression are reported to significantly decrease in response to hepatic inflammation, steatosis, and the progression of NAFLD in the liver (56–58), as shown in this study in the CAS control group presenting more liver inflammation than SPI group results.

CYP4 family of enzymes has been reported to increase its expression after feeding SPI vs. CAS (59). The ability of some CYP4 subfamily members to break down and metabolize pro- and anti-inflammatory leukotrienes illustrates that this subfamily may have an important role in the activation and resolution stages of inflammatory responses in the body (60). CYP4F8 utilizes prostaglandin E (PGE) synthase isomerase of prostaglandin endoperoxides (PGH1) and (PGH2) to metabolize PGH1 and PGH2 to 19-OH PGE1 and 19-OH PGE 2. PGE is known to have a large effect on cytokine synthesis and therefore can play an important role in the resolution phase of inflammation (61). CYP4F proteins are noted to play a role in lipid homeostasis by affecting lipid accumulation during the progression from steatosis to steatohepatitis through the stimulation of inflammatory immune cells (61). These previous reports concur with our results. The fact that CYP4F8 was strongly upregulated in the present study at both 8 and 16 weeks of SPI-fed rats (Table 3) and, consequently, downregulated in CAS-fed rats, may indicate an important role that CYP4F8 could be playing in reducing liver inflammation, which is observed to be decreased in the livers of SPI-fed rats. In addition, CYP4A14 upregulation was shown in the livers of patients with NAFLD and in several murine NAFLD models, and a deficiency or inhibition of CYP4A14 has been established to decrease hepatic inflammation and fibrosis (62). Our results corroborate this statement since CYP4A14 was downregulated after 16 weeks of SPI diet (Table 2), and its downregulation could be directly related to the observed amelioration of liver steatosis in obese Zucker rats.

Aryl hydrocarbon receptor is a ligand-activated helix-loop-helix cytosolic transcription factor involved in the control of main functions such as cell proliferation, differentiation, immune system, and apoptosis (Figure 2) (63, 64). AHR is a known regulator of xenobiotic metabolism, along with pregnane-X-receptor (PXR), constitutive androstane receptor (CAR), and peroxisome proliferator-activated receptor alpha (PPARα) (65). Upon ligand binding, the translocation of AHR into the nucleus occurs where it regulates the expression of many target genes, including xenobiotic-metabolizing enzymes such as CYP1A1 and CYP1A2 (64, 66). AHR has been extensively studied in its relationship with CYP1A1 and cancer prevention (67–69). Studies have shown that flavonoids and other natural compounds in the diet are mostly AHR agonists but that there are also studies that classify them as AHR antagonists (68). There is also evidence that the expression of CYP1A1 has protective effects against liver steatosis (70). Dietary flavonoids have also shown to have a protective role in gastrointestinal inflammation, probably acting on the gut microbiota and regulating interactions with AHR and estrogen receptors (71). Through the direct upregulation of CYP1A2 observed in this study and the indirect (prediction of) inhibition of important functions of the inflammatory response, such as the recruitment of phagocytes (Figure 3B), the activation of AHR by SPI diet could be contributing to the attenuation of inflammation in the liver tissue. Previously, we discussed how the SPI diet could be reducing liver steatosis by enhancing the lipid metabolism of the liver and inhibiting the inflammatory response in the liver tissue (37). The predicted activation of AHR by SPI feeding in this study could be part of the explanation for the observed amelioration of liver steatosis in SPI-fed obese rats compared with CAS-diet-fed rats.

We consider it important to highlight that CYP protein isoforms and their expression can vary between rodent models and humans, in addition to the utilization of different animal models and experimental designs (72, 73). However, studies have shown a correlation between obesity and NAFLD with the upregulation or downregulation of particular CYP families that could be triggered by inflammatory mediators such as interleukin 1β (IL-1β) and IL-6 (74, 75). Serum levels of these inflammatory mediators are usually increased in obese patients with NAFLD and the obese Zucker rat model, as reported in the studies by Hakkak et al. (29) and Kozaczek et al. (30). We also reported how feeding SPI reduces the expression of inflammation-related genes, such as IL-33 and IL-1β, that could be helping in the general reduction of liver steatosis observed with the SPI diet (31). In humans, studies have described a reduction in the expression of CYP3A family related to liver inflammation (76), and a study by Woolsey et al. (77) reported a reduction of CYP3A family in humans and a murine model for NAFLD. In 2017, Maximos et al. (78) linked a decrease in the expression of CYP3A25 with liver inflammation in C57BL6 mice, a model of obesity-dependent diabetes. In our study, only CYP3A62 from the CYP3A family has been decreased after the short- and long-term SPI feeding, whereas CYP3A7 and CYP3A25 have been significantly increased in SPI-fed rats, which can be correlated with the decreased
liver inflammation observed in this dietary group. Maximos et al. (78) also related obesity and its detrimental effects to a decrease in the expression of CYP2B and CYP2C family members. A CYP2 impairment is related to a lower drug metabolic clearance (78), mostly CYP2C8 and CYP2C9, both upregulated in our study in the SPI-fed rats. Despite disparities in many human and animal studies, the results show changes (upregulation and downregulation) in CYP expression in an obese and NAFLD rat model after the diet intervention in CYP that have been previously related to obesity and/or the presence of NAFLD.

CONCLUSIONS
In summary, through global gene expression analysis, we found that the gene expression of drug-metabolizing CYP genes was modified in NAFLD obese Zucker rat model after being fed a soy-based diet for short and long terms and that this change could have an important role in the attenuation of liver steatosis.

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/ (GSE158553).

ETHICS STATEMENT
The animal study was reviewed and approved by the Institutional Animal Care and Use Committee at the University of Arkansas for Medical Sciences authorized the animal codes (Protocol code number 3242).

AUTHOR CONTRIBUTIONS
RH was involved in experimental design. MK and DA were involved in targeted mRNA analysis. MK, WB, and RH were involved in data analysis and interpretation. MK and DA were involved in writing the original draft preparation. MK, WB, DA, and RH were involved in writing the review and editing. All authors have read and agreed to the published version of this manuscript.

FUNDING
This funding was provided by the College of Medicine’s University Medical Group (RH) and the Arkansas Biosciences Institute (WB and RH).

REFERENCES
1. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. (2019) 15:288–98. doi: 10.1038/s41574-019-0176-8
2. Chooy C, Ding C, Magkos F. The epidemiology of obesity. Metabolism. (2019) 92:6–10. doi: 10.1016/j.metabol.2018.09.005
3. Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD. Hepatol Commun. (2020) 4:136–48. doi: 10.1002/hpc2.1534
4. Cotter TG, Rinella M. Nonalcoholic fatty liver disease (NAFLD): an emerging health crisis. Curr Opin Gastroenterol. (2016) 32:559–65. doi: 10.1093/cocci/004.10.581
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. (2016) 64:73–84. doi: 10.1002/hep.28431
6. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. (2015) 62:S47–4. doi: 10.1016/j.jhep.2014.12.012
7. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. (2017) 288:1–8. Available online at: https://stacks.cdc.gov/view/cdc/49223
8. Ekstedt M, Nasr P, Kecharis A. Natural history of NAFLD/NASH. Curr Hepatol Rep. (2017) 16:391–7. doi: 10.1007/s11901-017-0378-2
9. Nyberg LM, Cheetham TC, Patton HM, Yang S, Chiang KM, Caparosa SL, et al. The natural history of NAFLD, a community-based study at a large health care delivery system in the United States. Hepatol Commun. (2021) 5:83–96. doi: 10.1002/hpc2.1625
10. Colognesi M, Gabbia D, De Martin S. Depression and cognitive impairment—Extrahepatic manifestations of NAFLD and NASH. Biomedicines. (2020) 8:229. doi: 10.3937/biomedicines080229
11. Merrell M, Cherrington N. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. (2011) 43:317–34. doi: 10.3109/03602523.2011.577781
12. Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. (2017) 21:1–20. doi: 10.1016/j.clld.2016.08.001
13. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. (2018) 19:38–54. doi: 10.2174/138945011866617021514557
14. Bernasconi C, Pelkonen O, Andersson T, Strickland J, Wilk-Zasada I, Asturid O, et al. Validation of in vitro methods for human cytochrome P450 enzyme induction: outcome of a multi-laboratory study. Toxicol In Vitro. (2019) 60:212–28. doi: 10.1016/j.tiv.2019.05.019
15. Tazak N, Bharatam P V. Drug metabolism. Resonance. (2014) 19:259–82. doi: 10.1007/s12045-014-0031-0
16. Rada P, González-Rodríguez A, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis. (2020) 11:802. doi: 10.1038/s41419-020-03003-w
17. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. (2011) 39:1954–60. doi: 10.1124/mdm.111.040592
18. George J, Murray M, Bryth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. (1995) 21:120–8. doi: 10.1002/hep.1840210121
19. Ioannides C. Effect of diet and nutrition on the expression of cytochromes P450. Xenobiotica. (1999) 29:109–54. doi: 10.1080/0049825992387804
20. Androutsopoulos VP, Papakyriakou A, Vorouloumis D, Tsatsakis AM, Spandides DA. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmocol Ther. (2010) 126:9–20. doi: 10.1016/j.pharmthera.2010.01.009
21. Li Y, Ross-Viola JS, Shay NF, Moore DD, Ricketts ML. Human CYP3A4 and murine Cyp3a11 are regulated by equal and genistein via the pregnane X receptor in a species-specific manner. J Nutr. (2009) 139:899–904. doi: 10.3945/jn.108.103572
22. Messina M. Soy and health update: evaluation of the clinical and epidemiologic literature. Nutrients. (2016) 8:754. doi: 10.3390/nu8120754
23. Badger T, Ronis M, Hakkak R, Rowlands J, Korourian S. The health consequences of early soy consumption. J Nutr. (2002) 132:559–65. doi: 10.1093/jn/132.3.559S
63. Vogel CFA, Haarmann-Stemmann T. The aryl hydrocarbon receptor repressor - More than a simple feedback inhibitor of AhR signaling: clues for its role in inflammation and cancer. Curr Opin Toxicol. (2017) 1:109–19. doi: 10.1016/j.cotox.2017.02.004

64. Wright EJ, De Castro KP, Joshi AD, Elferink CJ. Canonical and non-canonical aryl hydrocarbon receptor signaling pathways. Curr Opin Toxicol. (2017) 2:87–92. doi: 10.1016/j.cotox.2017.01.001

65. Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson T, Pelkonen O. Cytochrome P450 induction and xeno-sensing receptors pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor and peroxisome proliferator-activated receptor α at the crossroads of toxicokinetics and toxicodynamics. Basic Clin Pharmacol Toxicol. (2018) 123:42–50. doi: 10.1111/bcpt.13004

66. Kasar S, Kikuchi H. The inhibitory mechanisms of the tyrosine kinase inhibitors herbimycin A, genistein, and tyrphostin B48 with regard to the function of the aryl hydrocarbon receptor in caco-2 cells. Biosci Biotechnol Biochem. (2010) 74:36–43. doi: 10.1271/bbb.90438

67. Froyen EB, Steinberg FM. Genistein decreases basal hepatic cytochrome P450 1A1 protein expression and activity in Swiss Webster mice. Nutr Res. (2016) 36:430–9. doi: 10.1016/j.nutres.2016.01.001

68. Yang T, Feng YL, Chen L, Vaziri ND, Zhao YY. Dietary natural flavonoids treating cancer by targeting aryl hydrocarbon receptor. Crit Rev Toxicol. (2019) 49:445–60. doi: 10.1080/10408444.2019.1635987

69. Donovan MG,Selmin OI, Doetschman TC, Romagnolo DF. Epigenetic activation of BRCA1 by genistein in vivo and triple negative breast cancer cells linked to antagonism toward aryl hydrocarbon receptor. Nutrients. (2019) 11:2559. doi: 10.3390/nu11112559

70. Uno S, Nebert DW, Makishima M. Cytochrome P450 1A1 (CYP1A1) protects against nonalcoholic fatty liver disease caused by Western diet containing benzo [a] pyrene in mice. Food Chem Toxicol. (2017) 113:73–82. doi: 10.1016/j.fct.2018.01.029

71. Jin UH, Park H, Li X, Davidson LA, Allred C, Patil B, et al. Structure-dependent modulation of aryl hydrocarbon receptor-mediated activities by flavonoids. Toxicol Sci. (2018) 164:205–17. doi: 10.1093/toxsci/kfy073

72. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmaceutics. (2004) 450:1–18. doi: 10.1097/00008571-200401000-00001

73. Wang M, Tian X, Leung L, Wang J, Houvig N, Xiang J, et al. Comparative pharmacokinetics and metabolism studies in lean and diet-induced obese mice: an animal efficacy model for 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) inhibitors. Drug Metab Lett. (2011) 5:55–63. doi: 10.2174/187231211794455280

74. Mirea AM, Tack CJ, Chavakis T, Joosten LAB, Toonen EJM. IL-1 family cytokine pathways underlying NAFLD: towards new treatment strategies. Trends Mol Med. (2018) 24:458–71. doi: 10.1016/j.molmed.2018.03.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Kozaczek, Bottje, Albataineh and Hakkak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.